Effect of anti-obesity drug orlistat (Xenical™) on liver and kidney function in male rats fed a high-fat diet
F1000Research · 31.03.2026 · 15 · 136
DOI: 10.12688/f1000research.174090.2 ↗Kurz gefasst
Fachartikel in der Zeitschrift F1000Research, online erschienen am 31.03.2026. Verfasst von Sura M Alkadhimy und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biology, College of Science, University of Karbala, Karbala, Iraq. Hauptthemen laut MEDLINE: Orlistat, Diet, High-Fat, Anti-Obesity Agents, Liver. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
HFDs have adverse effects on metabolic health, which puts individuals at risk of obesity and liver and kidney dysfunction. Orlistat is an antihypertensive agent against obesity that prevents the absorption of dietary fats, although its impact on hepatic and renal functions is still disputed. In this study, the dose-dependent effects of orlistat on liver and renal functioning were in male rats on an HFD were assessed.
Methods
There was a control HFD group and three HFD groups with orlistat (360, 480 and 600 mg/kg) on male rats over 60 days. Lipid profiles, liver enzymes (AST, ALT, GGT, ALP), kidney (urea, creatinine, direct and indirect bilirubin), and hematological (hemoglobin, hematocrit, RBC, WBC counts, MCV, MCH, MCHC) serum tests were done. Histopathological analysis of liver and kidney tissues was done.
Findings
Orlistat caused dose-related changes in lipid profiles, increased liver enzymes, and an increased mark of kidney functioning. The hematological parameters were also greatly impaired, and the histopathology indicated structural and tissue damage in both of the organs, more so at higher doses.
Conclusions
Orlistat was used in HFD-conditions in male rats, which resulted in severe dose-related impairment of the liver and kidney. These results highlight the importance of close observation of hepatic and renal functions when using orlistat especially in the high-fat dietary situation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biology, College of Science, University of Karbala, Karbala, Iraq.
- Department of Environment, College of Science, University of Al-Qadisiyah, Al-Qadisiyah, Iraq.
- Department of Biology, College of Education, University of Fallujah, Al-Fallujah, Iraq.
- Department of Pathology and Poultry Disease, College of Veterinary Medicine, University of Fallujah, Al-Fallujah, Iraq.
- Department of Environmental Studies,Institute of Graduate Studies and Research, Alexandria University,163 Horeya Avenue, Chatby 21526, P.O. Box 832,Alexandria, Egypt.
ORCID-Profile: Sura M Alkadhimy, Asmaa M Neamah, Mohammed Y I Al-Hamadani
Zitieren
APA
Alkadhimy, S. M., Neamah, A. M., Al-Hamadani, M. Y. I., Jarad, A. S., & I Yousef, M. (2026). Effect of anti-obesity drug orlistat (Xenical™) on liver and kidney function in male rats fed a high-fat diet. F1000Research, 15, 136. https://doi.org/10.12688/f1000research.174090.2
Vancouver
Alkadhimy SM, Neamah AM, Al-Hamadani MYI, Jarad AS, I Yousef M. Effect of anti-obesity drug orlistat (Xenical™) on liver and kidney function in male rats fed a high-fat diet. F1000Research. 2026;15:136. doi:10.12688/f1000research.174090.2
BibTeX
@article{Alkadhimy2026,
author = {Alkadhimy, Sura M and Neamah, Asmaa M and Al-Hamadani, Mohammed Y I and Jarad, Ahmed S and I Yousef, Mokhtar},
title = {Effect of anti-obesity drug orlistat (Xenical™) on liver and kidney function in male rats fed a high-fat diet},
journal = {F1000Research},
year = {2026},
volume = {15},
pages = {136},
doi = {10.12688/f1000research.174090.2}
}
EUVIMED